<DOC>
	<DOCNO>NCT00002546</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . It yet know whether radiation therapy effective combination chemotherapy treat patient cancer uterus . PURPOSE : This randomized phase III trial study radiation therapy see well work compare combination chemotherapy treat patient cancer uterus .</brief_summary>
	<brief_title>Radiation Therapy Compared With Combination Chemotherapy Treating Patients With Cancer Uterus</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival , progression-free interval , failure pattern patient optimally debulked stage I-IV carcinosarcoma uterus treat whole abdominal radiotherapy v ifosfamide cisplatin . - Compare incidence type acute late adverse event observe treatment regimen patient population . OUTLINE : This randomize , multicenter study . Patients randomize one two treatment arm . - Arm I : Patients receive whole abdominal radiotherapy 5 day week 4 week , follow radiotherapy boost pelvis 5 day week 2.2 week . - Arm II : Patients receive cisplatin IV follow ifosfamide IV 1 hour day 1-4 . Treatment continue every 3 week 3 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 216 patient accrue study within 6 year .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Carcinosarcoma</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary homologous heterologous carcinosarcoma uterus ( corpus cervix ) Surgical stage IIV disease , include positive adnexa , tumor invade serosa , positive pelvic and/or paraaortic node , involvement mucosa bowel , bladder , rectum , intraabdominal metastasis , positive pelvic washing , vaginal involvement within plan radiation port Prior total abdominal hysterectomy bilateral salpingooophorectomy maximum tumor resection gross intraabdominal/pelvic disease , include grossly involve pelvic paraaortic node within 8 week study No great 1 cm residual disease Cervical sarcoma also allow No metastasis beyond abdominal cavity diagnosis , include follow : Parenchymal liver metastasis Lung metastasis Positive inguinal lymph node Positive scalene node Radiographic pathologic evidence bone brain metastasis PATIENT CHARACTERISTICS : Age : 21 Performance status : GOG 02 Hematopoietic : WBC least 3,000/mm3 Granulocyte count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 1.5 time normal SGOT great 3 time normal Albumin least 3 g/dL No acute hepatitis Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Other : No septicemia No severe infection No severe gastrointestinal bleeding No prior invasive concurrent malignancy within past 5 year except nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior hormonal therapy allow Radiotherapy : See Disease Characteristics No prior radiotherapy Surgery : See Disease Characteristics Other : No prior therapy would preclude study therapy</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>stage I uterine sarcoma</keyword>
	<keyword>stage II uterine sarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
</DOC>